1/14/2021 8:07:11 AM
Lipocine Reports USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications
1/12/2021 8:11:20 AM
Lipocine Announces Positive Topline Phase 2 Results From LPCN 1144 Ongoing LiFT Study; Stock Surges
12/30/2020 8:07:20 AM
Lipocine Says Enrolling Patients Into Open Label Extension To Ongoing LPCN 1144 Phase 2 LiFT Study
12/29/2020 8:07:32 AM
Lipocine Updates On Jury Trial In Patent Infringement Lawsuit Against Clarus; Trial Postponed To February 8
12/8/2020 9:05:24 PM
Lipocine Announces Deletion Of Unauthorized Changes To Company's Website
11/10/2020 8:12:10 AM
Lipocine Q3 Net Loss $4.3 Mln Or $0.07/shr Vs. Net Loss Of $3.1 Mln Or $0.12/shr Prior Year